Community curated by people like you

Tau protein stories

May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source

00

Top claims

▪The Phase 2 study of diranersen failed to achieve its primary efficacy goal, which was a dose response
▪Biogen investigated three escalating dosing regimens in the Phase 2 study of diranersen
▪Diranersen targets the protein tau, which is toxic to neurons and is believed to play a role in cognitive decline in Alzheimer's patients

Topics

Alzheimer’s & dementia Drug Approval and Clinical Trials Alzheimer's disease Pharma Clinical trials Mental health Drug development